Plastic Chemicals in Pediatric Cardiopulmonary Bypass: Evaluating Cardiac Toxicity and Investigating Clinical Alternatives
儿科心肺绕道中的塑料化学品:评估心脏毒性并研究临床替代方案
基本信息
- 批准号:10677964
- 负责人:
- 金额:$ 4.37万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-06-01 至 2026-05-31
- 项目状态:未结题
- 来源:
- 关键词:1 year oldAddressAdoptedAgeArrhythmiaBiocompatible MaterialsBloodBypassCalciumCalcium SignalingCannulasCardiacCardiac Electrophysiologic TechniquesCardiac MyocytesCardiac Surgery proceduresCardiac healthCardiologyCardiopulmonary BypassCardiotoxicityCardiovascular PhysiologyCellsChemical ExposureChemicalsChildhoodClinicalConfocal MicroscopyDataDecision MakingDevelopmentDevicesDiethylhexyl PhthalateExposure toFresh Frozen PlasmasFutureGap JunctionsGoalsHealthHeartHumanImpairmentInfantInterventionLaboratory ResearchLiquid substanceLow Cardiac OutputManufacturerMapsMedicalMedical DeviceMethodologyMethodsMicroelectrodesModelingMyocardiumNeonatalOpticsOutcomePatientsPediatric HospitalsPerioperativePhysiologicalPhysiologyPlasticizersPlasticsPolyvinyl ChloridePostoperative PeriodPre-Clinical ModelPreparationPrevalenceProceduresRecommendationReportingReproductive HealthResearch Project GrantsRiskSafetyTechnical ExpertiseTechniquesToxic effectTrainingTranslational ResearchTubeUnited StatesUnited States Food and Drug AdministrationWeightWhole Bloodblood productbody systemboysclinically relevantefficacy evaluationendotrachealexperienceflexibilityhigh riskimprovedinsightintercellular communicationmanufacturemono-(2-ethylhexyl)phthalateneonatepediatric patientsphthalatesresponsestem cell derived tissues
项目摘要
Project Summary
Phthalates are a type of plasticizer that are used to make rigid polyvinyl chloride (PVC) plastic flexible. In medical
devices, phthalate levels have been reported to be between 20-80% of a product’s weight depending on the type
of device; however, questions have arisen over their safety. The most common phthalate plasticizer used in PVC
medical devices is di(2-ethylhexyl) phthalate (DEHP). Patients undergoing cardiac surgery involving the use of
a cardiopulmonary bypass (CPB) circuit are exposed to significant levels of DEHP from blood products, circuitry
tubing, bypass cannulas, and endotracheal tubes. Despite the immeasurable benefits of plastics – there is
increasing concern over the potential health risks of phthalate chemical exposures. Accordingly, there is an
urgent need to develop and adopt safer alternatives to be used in pediatric CPB. The proposed research
project will address this need by evaluating the cardiotoxic effects of DEHP on the pediatric heart and
investigating potential mitigation strategies to reduce exposure to toxic phthalate chemicals. Aim 1 will
assess the direct effects of phthalate plasticizers on human pediatric cardiac electrophysiology and contractility.
Aim 2 will determine the efficacy of potential mitigation strategies to reduce phthalate exposure and improve
cardiac outcomes. The latter will include investigating the cardiac safety profile of commercially available DEHP-
free alternatives and the utility of using cell washing to remove phthalate plasticizers from cardiopulmonary
bypass fluids. The results of this proposal will largely be applicable to the fields of cardiology, with the potential
to inform regulatory decision making over the use of phthalate plasticizers in medical device manufacturing. This
is particularly important for medical devices that are used to treat vulnerable neonates and infants undergoing
cardiopulmonary bypass. This application contains a three-year training plan that will further my scientific
development, by building upon the expertise of my Sponsor (Dr. Posnack with expertise in cardiac
electrophysiology and cardiotoxicity) and co-Sponsor (Dr. Ishibashi with experience in preclinical models and
pediatric cardiac surgery). I will also benefit from a broader group of collaborators, who will provide insight into
clinical relevance and experimental techniques. This training proposal will expand my scientific understanding of
pediatric cardiovascular physiology, plasticizer toxicity, and clinically relevant models while supporting my future
goal to lead a translational research laboratory at a top children’s hospital.
项目摘要
邻苯二甲酸酯是一种增塑剂,用于使硬质聚氯乙烯(PVC)塑料变软。医疗
据报道,邻苯二甲酸酯含量在产品重量的20-80%之间,具体取决于产品类型。
然而,人们对其安全性提出了质疑。PVC中最常用的邻苯二甲酸酯增塑剂
邻苯二甲酸二(2-乙基己基)酯(DEHP)。接受心脏手术的患者涉及使用
心肺旁路(CPB)回路暴露于血液制品、回路
导管、旁路插管和气管内导管。尽管塑料有着不可估量的好处,
人们越来越关注邻苯二甲酸酯化学品暴露的潜在健康风险。因此,有一个
迫切需要开发和采用更安全的替代品用于儿科CPB。拟议研究
该项目将通过评估DEHP对儿童心脏的心脏毒性影响来满足这一需求,
调查潜在的缓解策略,以减少对有毒邻苯二甲酸酯化学品的暴露。目标1将
评估邻苯二甲酸酯增塑剂对人类小儿心脏电生理和收缩力的直接影响。
目标2将确定潜在缓解策略的有效性,以减少邻苯二甲酸酯暴露,
心脏结局。后者将包括研究市售DEHP的心脏安全性特征-
免费替代品和使用细胞洗涤去除心肺组织中邻苯二甲酸酯增塑剂的效用
分流液该提案的结果将在很大程度上适用于心脏病学领域,具有潜在的
为在医疗器械生产中使用邻苯二甲酸酯增塑剂的监管决策提供信息。这
这对于用于治疗经历了以下情况的脆弱新生儿和婴儿的医疗设备尤其重要:
体外循环这个应用程序包含一个三年的培训计划,将进一步我的科学
开发,通过建立在我的申办者的专业知识(Posnack博士,具有心脏病方面的专业知识
电生理学和心脏毒性)和共同申办者(具有临床前模型经验的Ishibashi博士,
小儿心脏手术)。我还将受益于更广泛的合作者群体,他们将提供以下方面的见解:
临床相关性和实验技术。这份培训计划将扩大我对以下问题的科学理解:
儿科心血管生理学、增塑剂毒性和临床相关模型,同时支持我的未来
他的目标是在一家顶级儿童医院领导一个转化研究实验室。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Devon Guerrelli其他文献
Devon Guerrelli的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 4.37万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 4.37万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 4.37万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 4.37万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 4.37万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 4.37万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 4.37万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 4.37万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 4.37万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 4.37万 - 项目类别:
Research Grant